Stocks · News reference
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
COMPASS Pathways announced it will present scientific research and educational content regarding treatment-resistant depression (TRD) at the 2026 Neuroscience Education Institute (NEI) Fall Congress.
Compass Pathways plc has scheduled the release of its financial results for the third quarter ended September 30, 2026, for November 3, 2026.
Compass Pathways (NASDAQ:CMPS) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected